Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1675
This examiner grants 32% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17598761 | MIXTURES OF SYNTHETIC COPOLYPEPTIDE HYDROGELS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17692494 | BIOADHESIVE COMPOSITION COMPRISING MUSSEL ADHESIVE PROTEIN AND PREPARATION METHOD THEREOF | Final Rejection | Postech Research and Business Development Foundation |
| 18312030 | ENGINEERING IMMUNE CHECKPOINT BLOCKADE NANOBODY-STING DELTA-TM FUSION PROTEIN AS A VERSATILE TREATMENT FOR SOLID TUMOR CANCERS | Non-Final OA | Massachusetts Institute of Technology |
| 17759355 | Designing Antisense Oligonucleotide Delivery Peptides by Interpretable Machine Learning | Non-Final OA | Massachusetts Institute of Technology |
| 17789099 | ENHANCING EXPRESSION OF LINE-1 ENCODED ORF2P FOR CANCER THERAPEUTICS | Final Rejection | The Johns Hopkins University |
| 17797275 | UNSATURATED FATTY ACID-CONJUGATED CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | Final Rejection | Industry-University Cooperation Foundation Hanyang University |
| 18523645 | THERAPEUTIC USES OF DULAGLUTIDE | Final Rejection | Eli Lilly and Company |
| 18251078 | COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY LUNG DISEASES | Non-Final OA | Arizona Board of Regents on Behalf of the University of Arizona |
| 18007879 | COMPOSITIONS AND METHODS FOR AUGMENTING AUTOLOGOUS FAT GRAFTS | Non-Final OA | Duke University |
| 17786384 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | Final Rejection | Agency for Science, Technology and Research |
| 18702790 | Polypeptide and its use as a CCK receptor agonist/antagonist | Final Rejection | City University of Hong Kong |
| 18235533 | BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS | Non-Final OA | BAYLOR COLLEGE OF MEDICINE |
| 18585339 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | Final Rejection | Ionis Pharmaceuticals, Inc. |
| 17434389 | ALBUMIN-BOUND COMPOSITION INCLUDING LRRD2 OF SLIT3 PROTEIN FOR PREVENTION OR TREATMENT OF BONE-RELATED DISEASES | Final Rejection | Daewoong Pharmaceutical Co., Ltd. |
| 18053308 | ANTISENSE THERAPEUTICS FOR BETACORONAVIRUS TREATMENT | Non-Final OA | The U.S.A., as Represented by the Secretary, Department of Health and Human Services |
| 18513964 | Methods for Reducing Risk of Onset of Acute Graft Versus Host Disease After Hematopoeitic Cell Transplantation | Final Rejection | CSL BEHRING LLC |
| 18019388 | ANTIMICROBIAL PEPTIDOMIMETICS | Non-Final OA | UNIVERSITÄT ZÜRICH |
| 18487666 | FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | Final Rejection | Zealand Pharma A/S |
| 17279691 | FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | Non-Final OA | Zealand Pharma A/S |
| 17276252 | FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | Final Rejection | Zealand Pharma A/S |
| 17911322 | POLYPEPTIDE AFFINITY LIGANDS AND METHODS OF USING | Non-Final OA | AVANTOR PERFORMANCE MATERIALS, LLC |
| 18186292 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | Non-Final OA | Bausch Health Ireland Limited |
| 17280802 | IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS | Final Rejection | SIGILON THERAPEUTICS, INC. |
| 18358601 | THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF | Final Rejection | Bioverativ Therapeutics Inc. |
| 18256201 | MEDICAMENT FOR INHIBITING DIETARY OBESITY AND POLYPEPTIDE USED THEREFOR | Non-Final OA | INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES |
| 18038607 | PEPTIDE HAVING PROTECTIVE ACTIVITY AGAINST CELL DAMAGE CAUSED BY PARTICULATE MATTER, AND USES FOR SAME | Non-Final OA | CAREGEN CO., LTD. |
| 18017582 | MATERIALS AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL RESPIRATORY DISEASES | Final Rejection | OAK CREST INSTITUTE OF SCIENCE |
| 18037926 | PD-L1 BINDING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Non-Final OA | Blaze Bioscience, Inc. |
| 18314035 | ENZYMATIC BIOCIDE FOR REMOVAL OF FOODBORNE MICROBIAL CONTAMINATION | Final Rejection | University of Virginia Patent Foundatuion |
| 17788179 | Methods for Treating Inflammatory Bowel Diseases with alpha4beta7 Integrin Antagonists | Non-Final OA | Protagonist Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy